Sionna director grants options for Enavate benefit
Sionna Therapeutics reported a new stock option grant connected to director Harold Edward Fleming’s board service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sionna Therapeutics reported a new stock option grant connected to director Harold Edward Fleming’s board service. The award covers 17,340 Non-Qualified Stock Options with an exercise price of $36.73 per share, expiring on June 16, 2036. According to the disclosure, Fleming has agreed to receive and hold these securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all rights in the option and the underlying shares. The option vests in full on the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to continued board service.
Insider Trade Summary
Grant/Award: 17,340 shares
Grant/Award
1 txn
Insider
Fleming Harold Edward
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 17,340 contracts (Direct)
Footnotes (2)
- F1. The Reporting Person has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.
- F2. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Key Figures
Option grant size: 17,340 options
Exercise price: $36.73 per share
Total options after grant: 17,340 options
+2 more
5 metrics
Option grant size
17,340 options
Non-Qualified Stock Options granted for director board service
Exercise price
$36.73 per share
Exercise price for the Non-Qualified Stock Option grant
Total options after grant
17,340 options
Total derivative securities held following the transaction
Option expiration date
June 16, 2036
Expiration date of the Non-Qualified Stock Options
Vesting trigger date
June 17, 2027
Latest vesting date, or earlier at next annual meeting
Key Terms
Non-Qualified Stock Option, beneficial ownership, vests in full, annual meeting
4 terms
Non-Qualified Stock Option financial
"The award covers 17,340 Non-Qualified Stock Options with an exercise price of $36.73 per share"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
beneficial ownership financial
"the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the option"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vests in full financial
"This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting"
annual meeting financial
"the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sionna Therapeutics (SION) disclose?
Sionna Therapeutics disclosed a grant of 17,340 Non-Qualified Stock Options related to director Harold Edward Fleming’s board service. The options give the right to buy common stock at a fixed exercise price if vesting conditions are met.
Who ultimately benefits from the new SION option grant?
The options are held for the benefit of Enavate Sciences, LP. The reporting director agreed to receive and hold any securities granted for Enavate’s benefit and disclaimed beneficial ownership and all rights, title, and interest in the option and underlying shares.
What are the key terms of the SION option grant’s vesting?
The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting. Vesting is conditioned on the reporting person’s continued service as a director through the applicable vesting date.
What is the exercise price and expiration date of the SION options?
The granted Non-Qualified Stock Options have an exercise price of $36.73 per share. They are scheduled to expire on June 16, 2036, providing a long-dated right to purchase Sionna Therapeutics common stock once vested.
How many SION derivative securities are held after this transaction?
Following the grant, the filing shows holdings of 17,340 derivative securities in the form of Non-Qualified Stock Options. This figure reflects the total option position reported after the award connected to the director’s board service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates